ClinicalTrials.gg
RecruitingNCT04573192GLIOSTARUpdated Apr 8, 2024

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

A Phase 1/2 interventional study of L19TNF and Lomustine in Glioblastoma, sponsored by Philogen S.p.A.. Recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Philogen S.p.A. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies in Glioblastoma with a site in Italy — 19 open to participants now, 30 under way, 5 of them phase 3. Glioblastoma · Italy.

Planned enrollment
31st of 75
142 · median 112
Started
2021
with 9 others
Phase 1/2
14 of 90
3 open now
Primary completion
2025-03
later than 3 of 29 live
Registered
52nd of 90
by date

Among the 90 studies in Glioblastoma with a site in Italy, this one is the 31st largest by planned enrollment of the 75 interventional ones that give a count, is one of 10 that started in 2021, is one of 14 in phase 1/2, reaches primary completion later than 3 of the 29 other live ones, and was the 52nd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

19 of the 90 studies in Glioblastoma with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Glioblastoma with a site in Italy, or all of them as a file.
02

Study summary

Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed.

L19TNF is a fully human fusion protein consisting of human tumor necrosis factor (TNF)-α fused to the L19 antibody in scFv format, specific to the extra-domain B of fibronectin. TNF not only induces apoptosis or necrosis in certain target cells, but also exerts inflammation and immunity. L19TNF selectively delivers TNF to the tumor site to spare normal tissues from undesired toxicity. Preclinical experiments with L19TNF have demonstrated tumor growth retardation in various mouse tumor models including models of glioma.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18.
  2. Patients with confirmed glioblastoma at unequivocal first recurrence or progression according to RANO criteria.
  3. MGMT promotor methylation status known
  4. IDH wildtype.
  5. Patients may have undergone surgery for recurrence.
  6. For operated patients: The histological report must document glioblastoma recurrence and a new MRI will need to be done at 3-5 weeks after surgery (directly before study treatment start). Study treatment will need to start minimum 4 weeks to maximum 6 weeks after surgery.
  7. Performance Status (KPS) ≥ 70%.
  8. Documented negative test for --. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  9. Female patients: female patients must be either documented not Women Of (WOCBP)* or must have a negative pregnancy test within 14 days of starting treatment. Additionally WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

    Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.

  10. Personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for glioblastoma at recurrence, except surgery.
  2. Surgical resection or of glioma within 4 weeks of the start of study treatment.
  3. Inability to undergo contrast-enhanced MRI.
  4. Prior treatment with lomustine.
  5. Known history of allergy to TNF or lomustine, any in the study medication or any other intravenously administered human proteins/peptides/antibodies.
  6. (ANC) \< 1.5 x 10\^9/L; \< 100 x 10\^9/L or (Hb) \< 9.0 g/dl.
  7. Chronically impaired renal function as indicated by \< 60 mL/min or serum creatinine > 1.5 .
  8. Inadequate liver function (, AST, ALP ≥ 2.5 x ULN or total ≥ 2.0 x ULN).
  9. > 1.5 ULN.
  10. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
  11. Active or history of disease that might deteriorate when receiving an immuno-stimulatory agent, in the judgement of the investigator.
  12. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  13. Heart insufficiency (> Grade II, (NYHA) criteria).
  14. cardiac arrhythmias or requiring permanent medication.
  15. \<55% or any other abnormalities observed during baseline and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current or a history of /QTc prolongation are excluded.
  16. Uncontrolled hypertension.
  17. Known arterial aneurism at high risk of rupture.
  18. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  19. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.
  20. Anxiety ≥ Grade 3.
  21. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  22. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  23. Known history of tuberculosis.
  24. Pregnancy or breast feeding.
  25. Requirement of chronic administration of high dose or other drugs. Subjects must have been either off corticosteroids, or on a stable or decreasing dose ≤ 4 mg daily dexamethasone (or equivalent) for 7 days prior to start of treatment. Limited or occasional use of corticosteroids to treat or prevent acute adverse reactions is not considered an exclusion criterion.
  26. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  27. Concurrent unless the patient has been disease-free without intervention for at least 2 years.
  28. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  29. Serious, non-healing wound, ulcer, or bone fracture.
  30. Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin).
  31. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  32. Any within 4 weeks prior to treatment or plan to receive live vaccination during the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Phase 1 part: Dose Finding

    Phase I part: Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels. The RD will be confirmed following a traditional 3+3 design. Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1.

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Phase II part: Signal Seeking

    118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle. * Treatment Arm 1: L19TNF plus Lomustine * Treatment Arm 2: Lomustine

    Drug: L19TNF · Drug: Lomustine

Interventions

  • DrugL19TNF

    Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

    Also known as: onfekafusp alfa

  • Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

06

What researchers measure

Primary outcomes

  1. For Phase 1: DLT

    Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.

    Time frame: For Cohort 1 to Cohort 3 from Day 1 to Day 42 after the first administration of lomustine and study drug (Cycle 1)

  2. For Phase 2: Overall Survival

    Overall survival (OS) rate

    Time frame: From beginning of treatment to 12 months

Secondary outcomes

  1. PFS

    Progression-free survival (PFS) based on iRANO criteria and a standardized MRI protocol will be assessed for all enrolled subjects.

    Time frame: From the date of enrollment to the date of progression or death for any cause, whichever came first, assessed up to 52 weeks

  2. PFS-rate at 6 months

    Progression-free survival (PFS) based on iRANO criteria and a standardized MRI protocol will be assessed for all enrolled subjects

    Time frame: From the date of enrollment to the date of progression or death for any cause, whichever came first, assessed up to 6 months

  3. OS-rate at 12 months

    Time frame: From beginning of treatment to 12 months

  4. Adverse Events (AE)

    Safety of administration of L19TNF, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient, a maximum of 52 weeks for each patient

  5. Serious Adverse Events (AE)

    Safety of administration of L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient, a maximum of 52 weeks for each patient

  6. Safety (DILI)

    Evaluation of possible Drug Induce Liver Injury, caused by L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient, a maximum of 52 weeks for each patient

07

Study locations

9 of 15 sites recruiting
  • Hôpital Neurologique Pierre Wertheimer
    Bron, France
    Not yet recruiting
    • François Ducray · Contact
  • Hôpital Saint Louis
    Paris, France
    Not yet recruiting
    • Stefania Cuzzubbo · Contact
  • Sorbonne University, AP-HP, Paris brain institute
    Paris, France
    Not yet recruiting
    • Ahmed Idbaih · Contact
  • University Hospital Bonn
    Bonn, Germany
    Recruiting
    • Ulrich Herrlinger · Contact
  • University Hospital Köln
    Köln, Germany
    Not yet recruiting
    • Norbert Galldiks · Contact
  • Klinikum rechts der Isar
    München, Germany
    Recruiting
    • Meike Mitsdörffer · Contact
  • Universitatsklinikum Tubingen
    Tübingen, Germany
    Recruiting
    • Ghazaleh Tabatabai · Contact
  • Azienda USL di Bologna IRCCS delle Scienze Neurologiche di Bologna
    Bologna, Italy
    Recruiting
    • Enrico Franceschi · Contact
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milano, Italy
    Recruiting
    • Antonio Silvani · Contact
  • Istituto Oncologico Veneto IRCCS
    Padova, Italy
    Recruiting
    • Giuseppe Lombardi · Contact
  • Azienda Ospedaliero-Universitaria Senese Policlinico Le Scotte
    Siena, Italy
    Not yet recruiting
    • Anna Maria Di Giacomo · Contact
  • AOU Città della Salute e della Scienza di Torino
    Torino, Italy
    Not yet recruiting
    • Alessia Pellerino · Contact
  • Inselspital Universitätsklinik für Medizinische Onkologie Bern
    Bern, Switzerland
    Recruiting
    • Marc Wehrli · Contact
  • Centre Hospitalier Universitaire Vaudois (CHUV)
    Lausanne, Switzerland
    Recruiting
    • Andreas Hottinger · Contact
  • Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum
    Zürich, CH-8091, Switzerland
    Recruiting
    • Tobias Weiss, MD · Contact+41 44 255 11 11
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Mar 2025, 49 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's planned 49 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 5, 2020
StartActual
Feb 19, 2021
Primary completionEst.
Mar 2025
CompletionEst.
Dec 2025
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04573192
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Feb 19, 2021
Primary completion
Mar 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 8, 2024

Study contacts

Teresa Hemmerle, PhD
Contact
regulatory@philogen.com
+390577017816
Marco Taras
Contact
regulatory@philogen.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onfekafusp alfa

Start the discussion